Ozempic vs Wegovy
Same Semaglutide Molecule — Different Dose, Indication, and Insurance Coverage
Ozempic and Wegovy share the exact same active ingredient: semaglutide. Ozempic is FDA-approved for type 2 diabetes at up to 2 mg weekly; Wegovy is approved for chronic weight management at up to 2.4 mg weekly. The different indication has significant downstream effects on insurance coverage and prescribing context. Track either formulation in Shotlee to monitor your dose and weight progress.
Ozempic vs Wegovy at a Glance
- →FDA indication: type 2 diabetes management
- →Dose range: 0.25 mg (starter) → 0.5 mg → 1 mg → 2 mg weekly
- →Maximum approved dose: 2 mg weekly
- →Often used off-label for weight loss by prescriber discretion
- →Weight loss in T2D trials: ~6–7 kg at 2 mg
- →Cardiovascular indication: reduces major CV events (SUSTAIN-6)
- →Insurance: generally covered for T2D indication
- →FDA indication: chronic weight management (BMI ≥30 or ≥27 + comorbidity)
- →Dose range: 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg over 16 weeks
- →Maximum approved dose: 2.4 mg weekly
- →Studied specifically for weight loss in STEP programme trials
- →Weight loss in STEP-1: ~14.9% body weight at 68 weeks
- →Cardiovascular benefit: SELECT trial (20% MACE reduction, 2023)
- →Insurance: variable coverage — many plans exclude obesity medications
Head-to-Head Comparison
| Factor | Ozempic | Wegovy |
|---|---|---|
| Active molecule | Semaglutide | SemaglutideBest |
| Manufacturer | Novo Nordisk | Novo Nordisk |
| FDA indication | Type 2 diabetes (+ CV risk reduction) | Chronic weight management |
| Maximum dose | 2 mg weekly | 2.4 mg weekly |
| Dose escalation | 4-week steps to 2 mg | 4-week steps to 2.4 mg over ~16 weeks |
| Key trial | SUSTAIN programme (T2D) | STEP-1 (obesity, N=1961) |
| Weight loss data | ~6–7 kg in T2D trials at 2 mg | 14.9% body weight at 2.4 mg (STEP-1) |
| Cardiovascular trial | SUSTAIN-6: positive for T2D | SELECT 2023: 20% MACE reduction (obesity) |
| Typical monthly cost (uninsured) | ~$900–1,000 | ~$1,300–1,400 |
| Off-label use | Often prescribed off-label for weight loss | Not typically prescribed off-label |
Weight Loss by Dose
Choose Based on Your Goal
You have type 2 diabetes
Ozempic is the established T2D-approved option with proven cardiovascular benefit. Most T2D insurance plans cover it.
Weight loss is the primary goal
Wegovy is specifically dosed and approved for obesity. STEP-1 showed 14.9% mean weight loss — the current obesity pharmacotherapy benchmark.
Insurance covers T2D but not obesity
Some patients use Ozempic off-label for weight loss when their plan excludes Wegovy. Discuss with your prescriber.
Cardiovascular risk reduction
SELECT used semaglutide 2.4 mg (Wegovy dose) and showed 20% MACE reduction in obesity with CVD. The molecule is the same across both brands.
Needle-free option preferred
Neither Ozempic nor Wegovy is oral. For needle-phobia, Rybelsus (oral semaglutide, T2D only) is an alternative.
Budget and access
Ozempic is typically less expensive and more widely available through insurance. Wegovy may have access challenges depending on your plan.
Which Should You Use?
The choice is largely driven by indication and insurance rather than pharmacology. If you have type 2 diabetes, Ozempic is the standard prescription with well-established T2D coverage. If weight management is the primary diagnosis, Wegovy is the indicated option with a higher maximum dose and a dedicated obesity approval.
Many patients with obesity but without T2D find their insurance does not cover Wegovy and are prescribed Ozempic off-label instead. While this is common practice, the dosing caps at 2 mg vs 2.4 mg for Wegovy, which may yield modestly less weight loss. The core molecule is identical.
The SELECT cardiovascular outcome trial (2023) used semaglutide 2.4 mg (Wegovy dosing) and showed a 20% reduction in MACE in people with obesity and existing cardiovascular disease — the strongest argument for Wegovy specifically in that population.
Ozempic vs Wegovy: Frequently Asked Questions
They share the same active ingredient, semaglutide, made by Novo Nordisk. The key differences are the maximum dose (2 mg vs 2.4 mg), the FDA indication (T2D vs obesity), and the pen device format.
Doctors can prescribe Ozempic off-label for weight management. The maximum dose is 2 mg vs Wegovy's 2.4 mg, which may result in slightly less weight loss. Insurance coverage for off-label use varies considerably.
Wegovy is priced higher partly due to its obesity indication, its higher-dose formulation, and its own pen device. Ozempic's broader T2D insurance coverage often makes it more accessible.
Wegovy at 2.4 mg showed 14.9% mean body weight loss in STEP-1. Ozempic at 2 mg shows ~6–7 kg in T2D populations. The difference reflects both dose and the different patient population studied.
Yes. The SELECT trial (2023) showed a 20% reduction in MACE with semaglutide 2.4 mg in people with obesity and established cardiovascular disease — making Wegovy the first obesity drug with a dedicated CV outcome trial win.
Track Ozempic or Wegovy in Shotlee
Log doses, weight, and side effects for semaglutide at any dose. Free for iOS and Android.
📚References & sources
Latest on Ozempic
Ozempic Muscle Loss: How a New Compound Preserves Strength
New research from Stanford Medicine reveals a potential solution to the muscle loss associated with GLP-1 medications like Ozempic and Wegovy, offering hope for stronger, healthier weight loss.
8 min read
Ozempic, Wegovy & Beyond: How GLP-1 Drugs Are Changing What We Eat
The rise of GLP-1 medications is profoundly altering consumer spending habits and food preferences, forcing the grocery industry to adapt. Discover the science behind these changes and how businesses are responding.
7 min read
Wegovy, Mounjaro & Your Libido: How GLP-1s Reshape Desire
GLP-1 medications have transformed weight management and diabetes care, but their effects extend beyond the scale. Many users report surprising changes to their libido and sexual function. This article delves into why these powerful drugs can either boost or dampen your sex drive, offering insights from leading medical experts.
9 min read